Clinical Trial Details
| Trial ID: | L2818 |
| Source ID: | NCT00562172 |
| Associated Drug: | Insulin Glargine |
| Title: | Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study) |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: Insulin glargine|DRUG: Glimepiride|DRUG: Metformin |
| Outcome Measures: | Primary: ß-cell Function parameter, From the signature of the Informed Consent Form (ICF) up to the end of study|Glucose Homeostasis and glycemic control status, From the signature of the Informed Consent Form (ICF) up to the end of study | Secondary: Insulin resistance parameter, Hypoglycemic episode, symptomatic, Weight change, Lipid profile, Inflammatory markers (CRP, Adiponectin, etcs), Patient satisfaction with diabetes treatment, Urine analysis, Creatinine, End of the study |
| Sponsor/Collaborators: | Sponsor: Sanofi |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 75 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2007-09 |
| Completion Date: | 2010-10 |
| Results First Posted: | |
| Last Update Posted: | 2012-07-17 |
| Locations: | Sanofi-aventis, Seoul, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT00562172 |
